Tirzepatide 20mg
Dual GIP/GLP-1 receptor agonist — high-dose vial for maintenance and advanced protocols.
Maintenance: 10 mg/week (2 doses) or 1.3 weeks at 15 mg/week
Key Benefits
10–15 mg/week doses produce full GIP + GLP-1 receptor engagement for peak metabolic response
22.5% mean body weight loss at 15 mg in SURMOUNT-1, outperforming all other approved weight-loss compounds
SURMOUNT-4 shows weight loss is maintained with continued dosing; discontinuation leads to significant regain
reduces visceral adiposity, improves lipid profiles, and lowers blood pressure at maintenance doses
Recommended Injection Sites
Optimal injection locations for Tirzepatide 20mg based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
FDA-approved clinical injection site for tirzepatide. Largest SubQ depot; most consistent absorption for weekly dosing.
Second preferred site per clinical guidelines. Equivalent AUC over weekly dosing interval.
Third approved site per Mounjaro/Zepbound prescribing information. Requires assistance for consistent placement.
Rotate weekly injection site systematically — abdomen → thigh → upper arm. Never inject the same exact spot twice in a row.
- IV administration
- Intramuscular injection (alters pharmacokinetics)
- Navel or waistband area
- Injection into skin folds with active lipodystrophy
Active Signaling Pathway
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 20mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. At maintenance doses (10–15 mg/week), the dual receptor mechanism produces maximal activation of both incretin pathways — GIP receptor agonism enhances insulin secretion and directly signals adipocytes, while GLP-1 receptor agonism suppresses appetite via hypothalamic pathways and delays gastric emptying.
Clinical Context
The 20mg vial is designed for researchers working with maintenance-phase protocols (10–15 mg/week). At these doses, tirzepatide demonstrates its full dual-mechanism efficacy. The SURMOUNT program is the largest obesity trial program ever conducted, with over 15,000 participants across multiple Phase 3 trials. FDA approved as Zepbound for chronic weight management in 2023.
Research Highlights
- SURMOUNT-1: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — highest of any approved weight-loss drug
- SURMOUNT-4: participants who continued tirzepatide after 36-week run-in maintained 5.5% additional weight loss vs 14% regain in placebo group
- SURPASS-CVOT: ongoing cardiovascular outcomes trial; interim data shows favorable cardiometabolic profile
- Phase 3 SURMOUNT-MMO trial: evaluating cardiovascular mortality benefit in obese patients without T2D
Storage & Reconstitution
Maintenance phase: 10 mg/week for 4 weeks, then 15 mg/week (maximum dose). This 20mg vial covers approximately 1–2 weeks of maintenance dosing.